

MEDICAMENT

MEDICAL MARIJUANA RESEARCH NEWSLETTER



SPRING 2022

**WELCOME TO
MEDICAMENT,**
the Consortium for Medical
Marijuana Clinical Outcomes
Research's quarterly newsletter.

The Consortium, founded by
the State of Florida, conducts,
disseminates, and supports
research on the use and effects
of medical marijuana on patient
outcomes.

In the Spring 2022 issue of
MEDICAMENT:

- Cannabis Clinical Outcomes
Research Conference
(CCORC) 2022
- 2021-22 Annual Report
- Evidence and Research
Announcements
- Medical Marijuana and Me
(M³)
- Get Involved in Research



Consortium for
Medical Marijuana
Clinical Outcomes Research

To learn more about the
Consortium and our programs,
visit us at mmjoutcomes.org.

CANNABIS CLINICAL OUTCOMES RESEARCH CONFERENCE (CCORC)

The Cannabis Clinical Outcomes Research Conference (CCORC) focuses on learning and sharing latest research findings, advancing medical marijuana research and promoting the dissemination of scientific evidence on the effects of marijuana, drug-drug interactions and safety.

CCORC 2022 connects researchers, physicians, community stakeholders, and industry leaders through two days of scientific presentations, panel discussions and poster sessions to expand our understanding of the effects of medical marijuana use on health.

CCORC

**CANNABIS CLINICAL OUTCOMES
RESEARCH CONFERENCE**

MAY 19TH - 20TH, 2022 | ORLANDO, FL

Learn, Share, and Advance Medical Marijuana Research

MORE INFORMATION AT CCORC.MMJOUTCOMES.ORG



Early bird registration ends April 29th, 2022. Take advantage of the early bird rate and register today for the Cannabis Clinical Outcomes Research Conference (CCORC).

Register Now!

CCORC is approved for Continuing Medical Education (CME) and Continuing Pharmacy Education Credits. The Cannabis Clinical Outcomes Research Conference will offer 1 CME/CPE credit for each of the three Keynote presentations.



May 19th, 9:30-10:45 AM (EST)

Keynote Presentation Titled: *Clarifying Cannabis: Considering the impact of recreational and medical use on cognitive and clinical outcomes*

Staci Gruber, Ph.D.

Director, Cognitive and Clinical Neuroimaging Core, McLean Hospital
Associate Professor of Psychiatry, Harvard Medical School



May 19th, 1:00-2:15 PM (EST)

Keynote Presentation Titled: *Effects of THC and CBD: Implications for Future Clinical Trials*

Kent Hutchinson, Ph.D.

Professor of Psychiatry, Anschutz Medical Campus
Adjunct Professor of Psychology and Neuroscience, University of Colorado in Boulder



May 20th, 8:15-9:30 AM (EST)

Keynote Presentation Titled: *Cannabis Use in Pain and as a Substitute for Opioids*

Samer Narouze, MD, Ph.D.

Associate Professor of Surgery, Northeast Ohio Medical University
Clinical Professor of Anesthesiology and Neurological Surgery, Ohio State University College of Medicine

CCORC announces program and schedule of events

The planning committee for the Cannabis Clinical Outcomes Research Conference is excited to share the program and schedule of events for May 19th and 20th, 2022.

The schedule includes keynote addresses by national experts in the field of cannabis research, panel discussions, as well as poster presentations and an exhibitor hall. View the full program [here](#)

2021-22 ANNUAL REPORT

The Consortium released its 2021-2022 Annual Report.

In February, the Consortium released its third annual report detailing its accomplishments from 2021-2022 and presenting plans for future initiatives.

[Read the 2021-2022 Annual Report.](#)

RESEARCH GRANTS PROGRAM

2022 Grants Program: Letters of Intent and Proposal

The Consortium for Medical Marijuana Clinical Outcomes Research received 17 letters of interest (LOI) from Faculty from 5 of its member institutions, in response to its fourth Request for Proposals (RFP) for the 2022 Research Grants Program. After review 16 LOIs were found to be responsive to the research priorities of the Consortium, and invited for full proposal submission. By the proposal deadline in April, 15 full proposals were received, which are currently under review. Final decisions as regards funding will be announced latest by July 1st, 2022.

EVIDENCE AND RESEARCH ANNOUNCEMENTS

What is Florida's medical marijuana research consortium studying – and what has it found so far?

Listen to the Consortium Director, Dr. Almut Winterstein, introduce the Consortium and its research...

[Read and hear the story.](#)

Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19?

A recent study reported that two cannabinoids, cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA), could block cellular entry of the virus that causes COVID-19 during in vitro experiments using cell cultures in a laboratory. Does this preclinical finding translate into humans?

[Read more to find out](#)

MEDICAL MARIJUANA & ME

Coming May 2022: Medical Marijuana and Me (M³)

After pilot testing survey questionnaires with medical marijuana patients and input from our valued provider and clinic partners, the Medical Marijuana & Me (M³) Study has received approval from the University of Florida Institutional Review Board and will begin

enrolling participants in May. M3 is prepared to seek the perspectives of 1,000 new and current medical marijuana patients and generate quality, high-impact evidence to inform clinical guidelines and improve patient health outcomes.

Medical Marijuana and Me will be the first large patient cohort in Florida that is followed to understand patient experience with medical marijuana. The Consortium will recruit at least 1,000 adult participants to complete a sequence of surveys about their general health, use and experiences with medical marijuana and related health outcomes.

Interested in participating or learning more?

Read about the study at mmjoutcomes.org/m3.

Are you a Medical Marijuana Qualified Physician interested in supporting recruitment?

Contact our study team at m3cohort@phhp.ufl.edu.



The poster features a large white 'M' with a cannabis leaf and the number '3' above it, all within a white square frame. Below this is the text 'Medical Marijuana & Me Research Study'. The words 'COMING SOON' are written in large, bold, white capital letters. At the bottom, it says 'LEARN MORE AT MMJOUTCOMES.ORG/M3' next to a QR code. A small 'UF' logo is in the top right corner. At the bottom left, there is a 'QUESTIONS' section with contact information: 'Call or text our team at (352) 659-9735' and 'Email our team at m3cohort@phhp.ufl.edu'. At the bottom right is the Consortium for Medical Marijuana Clinical Outcomes Research logo.

GET INVOLVED IN RESEARCH

Using or considering using medical marijuana in Florida and interested in research study participation?

Join the MMJ Registry

The Consortium maintains a registry of patients who are interested in being contacted to participate in medical marijuana studies.

Any current or future medical marijuana user in Florida can register their interest in participating in research.

By joining the MMJ Registry, you will help us with recruitment of patients for research studies and contribute to our understanding of the clinical benefits and side effects of medical marijuana.



JOIN THE MMJ REGISTRY

CARMMA: Changing the way we collaborate across the state of Florida
The [Connect and Advance Research for Medical Marijuana Analysis \(CARMMA\) Database](#) is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research. Anyone interested

in engaging in medical marijuana research is invited to register in CARMMA to find collaborators.

JOIN THE CARMA DATABASE

Have news or feedback to share?
Let us know!

Share your Consortium-related research
and news through our [submission form](#).

Share your comments on our newsletter
through our [feedback form](#).

Don't want to miss any
MEDICAMENT issues?

Share your contact information through
our [newsletter sign-up form](#).

[Read previous MEDICAMENT issues
at mmjoutcomes.org/newsletter.](http://mmjoutcomes.org/newsletter)



Consortium for
Medical Marijuana
Clinical Outcomes Research